Turning Point Therapeutics shares more than doubled on Friday

Shares of Turning Point Therapeutics Inc (NASDAQ: TPTX) more than doubled on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biotech company for $4.10 billion in cash.

Bristol-Myers to pay $76 a share for TPTX

The pharmaceutical giant is paying $76 a share for Turning Point that represents a 116% premium on the price at which TPTX closed the regular session on Thursday.

According to Bristol-Myers, it will use cash on hand to finance the acquisition that it forecasts will take until 2025 to be accretive to its non-GAAP per-share earnings. BMY is roughly flat on Friday.

The news comes weeks after Turning Point Therapeutics Inc reported wider-than-expected per-share loss for its fiscal first quarter.

Deal to close in the third quarter of 2022

Both Bristol-Myers and Turning Point have already secured approval from their respective boards. The transaction is expected to complete in the third quarter of 2022, subject to customary closing conditions.

TPTX Board of Directors have recommended that shareholders accept the tender offer. In the press release this morning, Turning Point Therapeutics Inc CEO Athena Countouriotis said:

With Bristol Myers’ leadership in oncology, strong commercial capabilities and manufacturing footprint, we’ll be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer.

The post Turning Point Therapeutics shares more than doubled on Friday appeared first on Invezz.

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 All Rights Reserved.

To Top